Maria-Fernanda González-Matamala

Maria-Fernanda González-Matamala

Auto-generated profile, based on publicly available information

Maria-Fernanda González-Matamala

Centro del Alergico Santiago de Chile Chile

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 June 2025 in Allergy
Verified
Journal Article
Open access
DLD. Loli‐Ausejo
D. Loli‐Ausejo
MGM. F. Gonzalez‐Matamala
M. F. Gonzalez‐Matamala
DMD. Martí
D. Martí
MRM. Ruano‐Zaragoza
M. Ruano‐Zaragoza
PIPatricia Mir Ihara
Patricia Mir Ihara
RMRosa Muñoz-Cano
Rosa Muñoz-Cano

26 February 2024 in Current Treatment Options in Allergy
Verified
Journal Article
Closed access
PDF file
PIPatricia Mir Ihara
Patricia Mir Ihara
MGMaria-Fernanda González-Matamala
Maria-Fernanda González-Matamala
MRMaria Ruano-Zaragoza
Maria Ruano-Zaragoza
DLDavid Loli-Ausejo
David Loli-Ausejo
LGLucia Garcia-Garcia
Lucia Garcia-Garcia
RMRosa Muñoz-Cano
Rosa Muñoz-Cano

30 August 2024
Verified
Preprint
Open access
MGMaria Gonzalez-Matamala
Maria Gonzalez-Matamala
MPMariona Pascal
Mariona Pascal
JBJordina Belmonte
Jordina Belmonte
CBClara San Bartolomé
Clara San Bartolomé
MRMaria Ruano-Zaragoza
Maria Ruano-Zaragoza
JBJoan Bartra
Joan Bartra

14 October 2026 in Pediatric Allergy and Immunology
Verified
Journal Article
Open access
MGM. F. Gonzalez‐Matamala
M. F. Gonzalez‐Matamala
NPN. Patel
N. Patel
DKD. Kahn‐Santoro
D. Kahn‐Santoro
Rebecca KnibbRebecca Knibb
Rebecca Knibb
GRG. Roberts
G. Roberts
TRThe Eaaci Taskforce On Food Allergen Ingestion Risk
The Eaaci Taskforce On Food Allergen Ingestion Risk
Introduction: Intranasal adrenaline has been approved in multiple countries for anaphylaxis treatment, based primarily on pharmacokinetic/pharmacodynamic comparisons to adrenaline autoinjectors (AAIs). Aim: To assess patient and caregiver perspectives regarding emerging non‐injectable adrenaline routes. Methods: Online survey of adults and caregivers of children with food allergy prescribed AAIs, with international dissemination supported by the European Academy of Allergy and Clinical Immunology (February–April 2025). Results: We analyzed 542 responses from caregivers and 224 from adults with food allergy. Effectiveness of adrenaline nasal spray (ANS) compared to AAI was rated “extremely important” by 78% of caregivers and 71% of adults. 48% of caregivers and 42% of adults were “extremely worried” that ANS may not work as well as AAI, and 50% and 44% (respectively) that it may not work well enough. Compared with AAI, respondents were less worried about ANS being painful or difficult to carry, and about fear/embarrassment around use, but more worried about side effects and knowing how to use it. Most anticipated being more comfortable using ANS than AAI, and over half anticipated earlier use during anaphylaxis. Only 17.2% of caregivers and 23.2% of adults preferred to be prescribed ANS only. There was interest in sublingual adrenaline due to portability and reduced needle‐related burden, but confidence depended on comparable speed/effectiveness and feasibility during reactions. Conclusions: Non‐injectable adrenaline is attractive to caregivers and adults, and may improve willingness to carry and use adrenaline. However, demand for evidence of effectiveness, safety, and real‐world feasibility is high, highlighting important information needs for shared decision‐making. image